PCV20 Vaccination Recommendation for Patient with Asthma and Prior PCV13
For an adult patient with asthma who previously received PCV13, administer a single dose of PCV20 at least 1 year after the PCV13 dose. 1
Age-Specific Guidance
If Patient is 19-64 Years Old with Asthma
Asthma is classified as a chronic lung disease, making this patient eligible for pneumococcal vaccination under the chronic medical conditions category 1
Administer PCV20 after a ≥1 year interval since the PCV13 dose 1
Alternative option: Administer PPSV23 after ≥1 year since PCV13, though PCV20 is preferred given the immunologic advantages of conjugate vaccines over polysaccharide vaccines 1
Review pneumococcal vaccine recommendations again when the patient turns 65 years to determine if additional vaccination is needed 1
If Patient is ≥65 Years Old
Administer a single dose of PCV20 after a ≥1 year interval since the PCV13 dose 1
This recommendation applies regardless of whether the patient has other immunocompromising conditions 1
If the patient had previously received both PCV13 and PPSV23 but the PPSV23 was given before age 65, still administer PCV20 after ≥5 years since the last dose 1
Rationale for PCV20
PCV20 provides protection against 7 additional serotypes beyond PCV13 (serotypes 8, 10A, 11A, 12F, 15B, 22F, and 33F), which continue to cause significant invasive pneumococcal disease 1, 2, 3
Conjugate vaccines like PCV20 offer immunologic advantages over PPSV23, including:
- More durable immune responses 1
- Better immunologic memory 1
- Superior protection compared to the limited duration of PPSV23 1
Safety Profile
PCV20 has demonstrated an acceptable safety profile similar to PCV13 across multiple clinical trials 4, 3, 5
Local reactions (redness, swelling, tenderness) and systemic events (fever, fatigue) are typically mild to moderate and transient 5, 6
The vaccine was well tolerated in adults with stable underlying medical conditions including chronic lung diseases 7
No concerning safety signals have emerged in adults previously vaccinated with PCV13 5
Important Clinical Considerations
Do not administer PCV20 and PPSV23 during the same visit if using the alternative PCV15/PPSV23 strategy 1
The minimum 1-year interval between PCV13 and PCV20 should be respected to optimize immune responses, though this can be shortened to 8 weeks only in patients with immunocompromising conditions, CSF leaks, or cochlear implants 1
Asthma alone does not qualify as an immunocompromising condition unless the patient requires long-term systemic corticosteroids at immunosuppressive doses 1